Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer

Nakatsukasa, Katsuhiko; Koyama, Hiroshi; Oouchi, Yoshimi; Imanishi, Seiichi; Mizuta, Naruhiko; Sakaguchi, Kouichi; Fujita, Yoshifumi; Fujiwara, Ikuya; Kotani, Tomoya; Matsuda, Takayuki; Fukuda, Kenichirou; Morita, Midori; Kawakami, Sadao; Kadotani, Yayoi; Konishi, Eiichi; Yanagisawa, Akio; Taguchi, Tetsuya

doi:10.1007/s12282-016-0666-7

Cited by 41 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nakatsukasa et al enrolled 52 breast cancer patients. Of them, 94.2% (49/52) patients completed 4 TC cycles and had an overall pCR rate of 16.3% (8/49); patients with luminal A-like breast cancer (ER + , Ki67 index < 20%, HER2 negative) had a pCR rate of 0% (0/12); patients with luminal B-like breast cancer (ER + , Ki67 index > 20%, HER2 negative) had a pCR rate of 4.3% (1/23); patients with TNBC had a pCR rate of 50.0% (7/14); almost all of the pCR occurred in TNBC breast cancer patients [34]. The results showed that neoadjuvant chemotherapy with TC was more suitable for the treatment of TNBC but had limited efficacy in treating other subtypes of breast cancer.…”

Section: Cyclophosphamidementioning

confidence: 99%

Triple-negative breast cancer molecular subtyping and treatment progress

et al. 2020

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Because TNBC tumors lack ER, PR, and HER2 expression, they are not sensitive to endocrine therapy or HER2 treatment, and standardized TNBC treatment regimens are still lacking. Therefore, development of new TNBC treatment strategies has become an urgent clinical need. By summarizing existing treatment regimens, therapeutic drugs, and their efficacy for different TNBC subtypes and reviewing some new preclinical studies and targeted treatment regimens for TNBC, this paper aims to provide new ideas for TNBC treatment.

show abstract

Section: Cyclophosphamidementioning

confidence: 99%

Triple-negative breast cancer molecular subtyping and treatment progress

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The objective of our study was to evaluate the efficacy of prophylactic anti-allergic drug administration against TC-related skin eruption in patients with primary breast cancer. This study is a subanalysis of data that we previously reported as part of a combined phase 2 study of TC NAC and HER-TC NAC [3,4]. This study was an openlabel, nonrandomized study, which was conducted at seven different institutions.…”

Section: Methodsmentioning

confidence: 99%

“…The cumulative incidence of skin eruption every chemotherapy cycle is summarized in Figure 3. As shown in Figure 3, the onset of skin efficacy and tolerability of TC neoadjuvant chemotherapy (NAC) and HER-TC NAC in patients with breast cancer in previous studies [3,4]. Therefore, in this work, we re-analyzed the data from those studies to retrospectively evaluate the prophylactic effectiveness of anti-allergic drugs against TC/HER-TC-related skin eruption among the patients in our clinical trial.…”

Section: Skin Toxicitiesmentioning

confidence: 99%

Prophylactic Anti-allergic Drug Administration to Prevent Docetaxel and Cyclophosphamide-induced Skin Toxicity: Sub-analysis of a Multiinstitution Neoadjuvant Chemotherapy Trial in Primary Breast Cancer Patients

Nakatsukasa¹,

Koyama²,

Ouchi³

et al. 2018

J Can Sci Res

View full text Add to dashboard Cite

TC and HER-TC are well known to cause skin eruption, indicating that they have a degree of non-hematological toxicity. However, the cause of this toxicity is unclear, and reliable treatment methods have not yet been established. As a result, prophylactic methods to prevent TC/ HER-TC-related skin eruption are urgently needed. Anti-allergic drugs are sometimes administered to treat skin eruption, but their prophylactic effectiveness has not yet been investigated. We hypothesized that the prophylactic use of anti-allergic drugs would decrease the incidence of TC/HER-TC-related skin eruption. We have already reported the

show abstract

“…Usually 600 mg/m² cyclophosphamide is intravenously (IV) administered to breast cancer patients in combination with other chemotherapeutics (Docetaxel, Paclitaxel, Doxorubicin). The recommended regimens for robustly healthy breast cancer patients include 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or 4 cycles of adriamycin and cyclophosphamide (AC) [71,72].…”

Section: Alkylating Agentsmentioning

confidence: 99%

Drug repurposing for breast cancer therapy: Old weapon for new battle

Aggarwal

Verma

Aggarwal

et al. 2021

Seminars in Cancer Biology

101

View full text Add to dashboard Cite

Despite tremendous resources being invested in prevention and treatment, breast cancer remains a leading cause of cancer deaths in women globally. The available treatment modalities are very costly and produces severe side effects. Drug repurposing that relate to new uses for old drugs has emerged as a novel approach for drug development. Repositioning of old, clinically approved, off patent non-cancer drugs with known targets, into newer indication is like using old weapons for new battle. The advances in genomics, proteomics and information computational biology has facilitated the process of drug repurposing. Repositioning approach not only fastens the process of drug development but also offers more effective, cheaper, safer drugs with lesser/known side effects. During the last decade, drugs such as alkylating agents, anthracyclins, antimetabolite, CDK4/6 inhibitor, aromatase inhibitor, mTOR inhibitor and mitotic inhibitors has been repositioned for breast cancer treatment. The repositioned drugs have been successfully used for the treatment of most aggressive triple negative breast cancer. The literature review suggest that serendipity plays a major role in the drug development. This article describes the comprehensive overview of the current scenario of drug repurposing for the breast cancer treatment. The strategies as well as several examples of repurposed drugs are provided. The challenges associated with drug repurposing are discussed. Current breast cancer therapyUnlike a decade ago, clinicians today have multiple choices for breast cancer treatment depending on the size, stage, grade, metastatic behavior, aggressiveness and intrinsic molecular subtyping of tumor, age, menopausal status, overall health, comorbidities, and preferences of the patient [9-13]. Chemotherapy, hormone therapy, immunotherapy, radiotherapy, and surgery are the common modalities for breast cancer [10,14]. Primary choice of treatment usually includes surgery with the aim of complete resection of the major tumor mass on the first hand. Breast conserving (lumpectomy) and breast reconstruction surgeries, mastectomy or lymph node dissections are performed initially in the breast cancer patients [15]. Surgery may be preceded with the systemic neoadjuvant therapies in order to shrink the tumor for effective surgery and to maximize breast conservation. For example, in HER2+ cases, Trastuzumab (Herceptin) and Pertuzumab (Perjeta)

show abstract

Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer

Cited by 41 publications

References 17 publications

Triple-negative breast cancer molecular subtyping and treatment progress

Triple-negative breast cancer molecular subtyping and treatment progress

Prophylactic Anti-allergic Drug Administration to Prevent Docetaxel and Cyclophosphamide-induced Skin Toxicity: Sub-analysis of a Multiinstitution Neoadjuvant Chemotherapy Trial in Primary Breast Cancer Patients

Drug repurposing for breast cancer therapy: Old weapon for new battle

Contact Info

Product

Resources

About